The Uro-Oncology Asia 2021 Significant advances in urological cancer treatments have been emerging in recent years. For instance, immunotherapy continues to play an increasingly important role and innovations in biomarkers help select patients for s...
Management of Relapsed and Refractory Multiple Myeloma Date: 25 February 2021 (Thursday) Time: 19:15 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Webinar on Management of Relapsed and Refractory Multiple Myeloma Multiple myeloma (MM) is charact...
Benefits of yogurt on gastrointestinal health have been widely investigated in numerous studies and regular yogurt consumption may contribute to the favorable gut microbiome. Recently, the data from 2 large, prospective cohort studies revealed that ...
Overview of Breast Cancer Treatments Dr. Li outlined that there are 3 major aspects for breast cancer treatment including surgery, radiotherapy and pharmacological treatment. For pharmacological treatment, in turns, there are 4 classes of therapies,...
The Importance of Systemic Treatment Sequencing in Improving Survival for Patients with Advanced Liver Cancer Dr.Catherine Frenette, Prof. Peter Galle, Dr.Richard Finn, Prof. Jean-Frédéric Blanc, Dr. Kirhan Özgürdal, Prof. An...
Diagnostic Imaging for HCC in Local Clinical Practice Currently, local guideline on diagnostic imaging for HCC is yet to be developed, whereas various international diagnostic guidelines such as the Asian Pacific Association for the Study of the Liv...
A Beacon of Hope for Patients with Metastatic Triple Negative Breast Cancer (mTNBC) Frequently afflicting young women below 50 years old, Triple Negative Breast Cancer (TNBC) accounts for 14% of breast cancer cases in Hong Kong 1 . Classified by the...
Relieving the Health Burden of Metastatic Castration-Resistant Prostate Cancer Prostate cancer is considered one of the most prevalent cancers in men worldwide. In Hong Kong, it is the fourth leading cause of male cancer deaths, with both age-standa...
Oncolytic Herpes Simplex Virus An Emerging Solution for Glioblastoma Glioblastoma (GBM) is one of the most aggressive and deadliest cancers with only few patients survive 2.5 years and less than 5% of patients survive 5 years following diagnosis 1 ....
Since June 2020, a webinar series known as Guerbet APAC TV so far has reached 81 countries/regions worldwide since it has been broadcasted. This year their 6 live webinars cover various topics in diagnostic imaging such as the application of artif...
Consolidation Therapy with Durvalumab “A revolutionary treatment of lung cancer has emerged in 2017. It is, durvalumab, a monoclonal antibody against programmed death ligand 1 (PD-L1). Physiologically, PD-L1 binds to its receptor programmed de...
Immune Checkpoint Inhibitor Therapy in Patients with Autoimmune Disorders: A Brief Review The clinical development of immune checkpoint inhibitors (ICIs), including those targeting the programmed cell death 1 and its ligand 1 (PD-1/PD-L1), or cytoto...
